KRAS and cancer: In GP12, top truncal druggable targets were the inactivation of BRCA2, and PTEN. Several druggable subclonal somatic cancer variants were further identified in both patients, such as AR, ESR1, EGFR, KRAS, and MET in GP5, and HRAS, TP53, KRAS, BRAF, and AKT1 in GP12.